FDA Cites Gleevec For Promoting Unapproved Indications Three Weeks Before Expanding Label
This article was originally published in The Pink Sheet Daily
Executive Summary
Notice of violation letter to Novartis from FDA’s Office of Prescription Drug Promotion expresses concern about describing a patient with five-year survival data, a claim that was added to the label the following month.